<p>Jubilant Pharmova on Monday said its arm Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of Covid-19 against the available injectable formulation of the antiviral drug in India.</p>.<p>Jubilant Pharma has successfully completed "safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir," Jubilant Pharmova said in a filing to BSE.</p>.<p>Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI), it added.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/west/govt-to-double-remdesivir-production-to-3-lakh-vials-per-day-in-15-days-mandaviya-975794.html" target="_blank">Govt to double Remdesivir production to 3 lakh vials per day in 15 days: Mandaviya</a></strong></p>.<p>"Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for Covid-19 patients. The proposed oral treatment is expected to be for five days, a duration similar to the injectable dosage form," Jubilant Pharmova said.</p>.<p>Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with Covid-19 requiring hospitalisation, it added.</p>.<p>"We are pleased to announce the ongoing development of a novel formulation of Remdesivir to address the pandemic at this critical juncture. Once approved, this will not only provide a more convenient and easy-to-administer formulation but also support an increasing demand of Covid-19 treatments,” Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman and MD Hari S Bhartia said.</p>.<p>In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc, that granted it the right to register, manufacture and sell Gilead's Remdesivir in 127 countries including India, the filing said.</p>.<p>On July 20, 2020, Jubilant received approval from the DCGI to manufacture and market Remdesivir for 100 mg/vial for restricted emergency use in India for the treatment of severe Covid-19, it added.</p>.<p>Shares of Jubilant Pharmova were trading at Rs 775.30 per scrip on BSE, up 7.07 per cent from its previous close.</p>
<p>Jubilant Pharmova on Monday said its arm Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of Covid-19 against the available injectable formulation of the antiviral drug in India.</p>.<p>Jubilant Pharma has successfully completed "safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir," Jubilant Pharmova said in a filing to BSE.</p>.<p>Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI), it added.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/west/govt-to-double-remdesivir-production-to-3-lakh-vials-per-day-in-15-days-mandaviya-975794.html" target="_blank">Govt to double Remdesivir production to 3 lakh vials per day in 15 days: Mandaviya</a></strong></p>.<p>"Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for Covid-19 patients. The proposed oral treatment is expected to be for five days, a duration similar to the injectable dosage form," Jubilant Pharmova said.</p>.<p>Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with Covid-19 requiring hospitalisation, it added.</p>.<p>"We are pleased to announce the ongoing development of a novel formulation of Remdesivir to address the pandemic at this critical juncture. Once approved, this will not only provide a more convenient and easy-to-administer formulation but also support an increasing demand of Covid-19 treatments,” Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman and MD Hari S Bhartia said.</p>.<p>In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc, that granted it the right to register, manufacture and sell Gilead's Remdesivir in 127 countries including India, the filing said.</p>.<p>On July 20, 2020, Jubilant received approval from the DCGI to manufacture and market Remdesivir for 100 mg/vial for restricted emergency use in India for the treatment of severe Covid-19, it added.</p>.<p>Shares of Jubilant Pharmova were trading at Rs 775.30 per scrip on BSE, up 7.07 per cent from its previous close.</p>